financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment
Feb 20, 2025 2:13 AM

04:45 AM EST, 02/20/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) and Sobi said Thursday that the European Medicines Agency has validated an indication extension application for Aspaveli to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The submission was based on the results from a phase 3 trial that met its primary endpoint by reducing proteinuria in pegcetacoplan-treated patients by 68% as compared to placebo, the companies added.

C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are two kinds of chronic kidney diseases without approved treatments.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Peabody Energy reviewing options related to deal with Anglo American
Peabody Energy reviewing options related to deal with Anglo American
Apr 8, 2025
April 8 (Reuters) - Peabody Energy ( BTU ) said on Tuesday it was reviewing all options related to its $3.78 billion potential acquisition of steelmaking coal assets from Anglo American. (Reporting by Vallari Srivastava in Bengaluru; Editing by Shinjini Ganguli) ...
 Accord Financial Swings to Fourth-quarter Loss on Lower Revenue
Accord Financial Swings to Fourth-quarter Loss on Lower Revenue
Apr 8, 2025
05:21 PM EDT, 04/08/2025 (MT Newswires) -- Accord Financial ( ACCFF ) after trade Tuesday said it swung to a fourth-quarter loss as its revenue declined year-over-year. The company lost $791,000, or $0.09 per share, in the period, compared with a profit of $3.70 million, or $0.43 per share, in the year-ago quarter. Revenue fell to $21.22 million from $23.90...
 Market Chatter: KKR Finalizing Terms to Buy Karo Healthcare in $2.7 Billion Deal
Market Chatter: KKR Finalizing Terms to Buy Karo Healthcare in $2.7 Billion Deal
Apr 8, 2025
05:19 PM EDT, 04/08/2025 (MT Newswires) -- KKR (KKR) is finalizing terms to acquire EQT AB-backed Karo Healthcare in a transaction that could value the Sweden-based consumer health firm at more than 2.5 billion euros ($2.7 billion), Bloomberg reported Tuesday, citing people familiar with the matter. Talks are in the final stages but could still be postponed or called off,...
 Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved